NZ512574A - Novel streptococcus antigens useful as vaccines - Google Patents

Novel streptococcus antigens useful as vaccines

Info

Publication number
NZ512574A
NZ512574A NZ512574A NZ51257499A NZ512574A NZ 512574 A NZ512574 A NZ 512574A NZ 512574 A NZ512574 A NZ 512574A NZ 51257499 A NZ51257499 A NZ 51257499A NZ 512574 A NZ512574 A NZ 512574A
Authority
NZ
New Zealand
Prior art keywords
vaccines
antigens useful
streptococcus
streptococcus antigens
novel streptococcus
Prior art date
Application number
NZ512574A
Other languages
English (en)
Inventor
Isabelle Pineau
Denis Martin
Clement Rioux
Nathalie Harland
Josee Hamel
Bernard R Brodeur
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ512574(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of NZ512574A publication Critical patent/NZ512574A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ512574A 1998-12-23 1999-12-20 Novel streptococcus antigens useful as vaccines NZ512574A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11380098P 1998-12-23 1998-12-23
PCT/CA1999/001218 WO2000039299A2 (en) 1998-12-23 1999-12-20 Streptococcus antigens

Publications (1)

Publication Number Publication Date
NZ512574A true NZ512574A (en) 2004-03-26

Family

ID=22351610

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ512574A NZ512574A (en) 1998-12-23 1999-12-20 Novel streptococcus antigens useful as vaccines

Country Status (29)

Country Link
EP (2) EP1141306B1 (https=)
JP (2) JP4761623B2 (https=)
KR (4) KR100891398B1 (https=)
CN (3) CN100398653C (https=)
AP (1) AP2001002199A0 (https=)
AR (1) AR029322A1 (https=)
AT (1) ATE394489T1 (https=)
AU (1) AU1764900A (https=)
BR (1) BR9916477A (https=)
CA (1) CA2356836C (https=)
CL (1) CL2009002037A1 (https=)
CY (3) CY1108223T1 (https=)
CZ (2) CZ302790B6 (https=)
DE (1) DE69938670D1 (https=)
DK (3) DK2261358T3 (https=)
EA (1) EA007409B1 (https=)
ES (3) ES2400280T3 (https=)
HU (1) HU229664B1 (https=)
IL (3) IL143905A0 (https=)
MX (1) MXPA01006427A (https=)
NO (1) NO330800B1 (https=)
NZ (1) NZ512574A (https=)
OA (1) OA11736A (https=)
PL (3) PL206576B1 (https=)
PT (3) PT1141306E (https=)
TR (2) TR200200633T2 (https=)
UY (1) UY25877A1 (https=)
WO (1) WO2000039299A2 (https=)
ZA (1) ZA200105114B (https=)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2540281T3 (es) 1998-02-20 2015-07-09 Id Biomedical Corporation Of Quebec Antígenos de estreptococos del grupo B
EP1801218A3 (en) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nucleic acids and proteins from streptococcus pneumoniae
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
ES2322306T3 (es) * 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
ES2400280T3 (es) * 1998-12-23 2013-04-08 Id Biomedical Corporation Of Quebec Antígenos de estreptococos
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
DE60136356D1 (de) * 2000-06-12 2008-12-11 Univ Saskatchewan Chimäres GapC Protein aus Streptococcus und dessen Verwendung zur Impfung und Diagnostik
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
AU2001270381B2 (en) 2000-06-20 2007-05-24 Id Biomedical Corporation Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
AU2002242549A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
WO2003004650A2 (en) * 2001-07-06 2003-01-16 Shire Biochem Inc. Group b streptococcus antigens and corresponding dna fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
EP1456231A2 (en) * 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigens
SI1601770T1 (sl) 2003-03-04 2010-01-29 Intercell Ag Streptococcus pyogenes antigeni
EP2333114A1 (en) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
PL1973564T3 (pl) 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
BRPI0814127A2 (pt) * 2007-07-23 2015-02-03 Sanofi Pasteur Ltd Polipeptídeos imunegênicos e anticorpos monoclonais
SI2271360T1 (sl) 2008-04-16 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo
EP2349209A2 (en) 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
AU2010243285B2 (en) 2009-04-30 2013-06-06 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
PE20161551A1 (es) 2009-09-03 2017-01-18 Pfizer Vaccines Llc Vacuna de pcsk9
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
KR20140009281A (ko) 2010-12-03 2014-01-22 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 스트렙토코커스 뉴모니애에 대한 면역화를 위한 조성물
US9393294B2 (en) 2011-01-20 2016-07-19 Genocea Biosciences, Inc. Vaccines and compositions against Streptococcus pneumoniae
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
WO2012156391A1 (en) 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
ES2642184T3 (es) * 2012-01-05 2017-11-15 Deutsches Krebsforschungszentrum Péptidos para su uso en el tratamiento y diagnóstico de cánceres positivos a IDH1 R132H
EP2931743A4 (en) * 2012-12-14 2016-08-03 Sanofi Pasteur Ltd METHOD FOR ASSESSING IMMUNOGENICITY
IL312327B2 (en) 2014-01-21 2026-02-01 Pfizer Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
CN120718167A (zh) 2014-01-21 2025-09-30 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112016016580B1 (pt) 2014-01-21 2024-01-09 Pfizer Inc Processo para a preparação de um conjugado imunogênico, conjugado imunogênico, composição imunogênica, e vacina
EP3104886B1 (en) 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates
CN107427568B (zh) 2015-01-15 2021-12-14 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
CN108367063A (zh) 2015-07-21 2018-08-03 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
BR112022001654A2 (pt) 2019-07-31 2022-07-12 Sanofi Pasteur Inc Composições conjugadas de proteinas de polissacarídeos pneumocócicos multivalentes e métodos de utilização dos mesmos
CA3159573A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3171864A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
NZ790372A (en) 2020-02-23 2026-01-30 Pfizer Escherichia coli compositions and methods thereof
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
KR20230097160A (ko) 2020-11-04 2023-06-30 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CN119317445A (zh) 2022-05-11 2025-01-14 辉瑞公司 用于生产含有防腐剂的疫苗制剂的方法
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
JP2025537898A (ja) 2022-11-22 2025-11-20 ファイザー・インク コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250163977A (ko) 2023-03-30 2025-11-21 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
EP4694921A1 (en) 2023-04-14 2026-02-18 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4701656A1 (en) 2023-04-24 2026-03-04 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
DK0656014T3 (da) * 1993-03-19 2003-08-11 Gunnar Lindahl Protein Rib, et celleoverfladeprotein der overfører immunitet mod mange gruppe B Streptococcus stammer, fremgangsmåde til oprensning af proteinet, reagenskit og farmaceutisk komposition
CZ394297A3 (cs) * 1995-06-07 1998-04-15 Biochem Vaccines Inc. Streptokokové proteiny teplotního šoku ze skupiny HSP70
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
JP4469026B2 (ja) * 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド Streptococcus pneumoniaeの抗原およびワクチン
EP1017828A1 (en) * 1997-09-24 2000-07-12 Regents Of The University Of Minnesota HUMAN COMPLEMENT C3-DEGRADING PROTEINASE FROM $i(STREPTOCOCCUS PNEUMONIAE)
JP2002516251A (ja) * 1998-04-23 2002-06-04 ユーエイビー リサーチ ファンデーション 肺炎球菌表面プロテインC(PspC)のエピトープ領域およびその菌株選択、ならびにそのための使用法
CN1318103A (zh) * 1998-07-27 2001-10-17 微生物技术有限公司 肺炎链球菌的核酸和蛋白质
DE69935986D1 (de) * 1998-07-27 2007-06-14 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
JP2002526082A (ja) * 1998-09-24 2002-08-20 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ストレプトコッカス・ニューモニア由来のヒト補体c3分解ポリペプチド
ES2322306T3 (es) * 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
ES2400280T3 (es) * 1998-12-23 2013-04-08 Id Biomedical Corporation Of Quebec Antígenos de estreptococos

Also Published As

Publication number Publication date
KR20010104693A (ko) 2001-11-26
EP2261358A2 (en) 2010-12-15
EA200100565A1 (ru) 2002-04-25
WO2000039299A2 (en) 2000-07-06
NO20013045D0 (no) 2001-06-19
ES2400280T3 (es) 2013-04-08
JP4761623B2 (ja) 2011-08-31
CZ302790B6 (cs) 2011-11-09
CN1654657A (zh) 2005-08-17
CZ303675B6 (cs) 2013-02-27
ES2306528T3 (es) 2008-11-01
HU229664B1 (en) 2014-04-28
CY1115340T1 (el) 2017-01-04
JP5039802B2 (ja) 2012-10-03
HK1118575A1 (en) 2009-02-13
DK1950302T3 (da) 2013-01-14
DK1141306T3 (da) 2008-08-18
KR101078919B1 (ko) 2011-11-01
EP1141306B1 (en) 2008-05-07
KR20060134227A (ko) 2006-12-27
IL143905A0 (en) 2002-04-21
PT1950302E (pt) 2013-01-16
PL206576B1 (pl) 2010-08-31
PL205041B1 (pl) 2010-03-31
IL194230A0 (en) 2011-08-01
CA2356836C (en) 2011-09-13
IL143905A (en) 2011-05-31
CN100398653C (zh) 2008-07-02
EP2261358A3 (en) 2011-02-23
EP1141306A2 (en) 2001-10-10
JP2010142246A (ja) 2010-07-01
PL349777A1 (en) 2002-09-09
KR100891398B1 (ko) 2009-04-02
WO2000039299A3 (en) 2000-11-02
DE69938670D1 (de) 2008-06-19
DK2261358T3 (da) 2014-07-28
BR9916477A (pt) 2004-06-22
CY1114722T1 (el) 2016-10-05
CA2356836A1 (en) 2000-07-06
CN1332803A (zh) 2002-01-23
OA11736A (en) 2005-06-12
NO20013045L (no) 2001-08-20
CZ20012161A3 (cs) 2001-10-17
EA007409B1 (ru) 2006-10-27
AP2001002199A0 (en) 2001-09-30
CL2009002037A1 (es) 2010-06-25
MXPA01006427A (es) 2002-06-04
JP2002533123A (ja) 2002-10-08
HUP0104774A3 (en) 2007-10-29
HUP0104774A2 (hu) 2002-04-29
KR20080036666A (ko) 2008-04-28
CY1108223T1 (el) 2014-02-12
TR200200633T2 (tr) 2002-06-21
KR20100063814A (ko) 2010-06-11
AR029322A1 (es) 2003-06-25
CN1191362C (zh) 2005-03-02
TR200102497T2 (tr) 2002-01-21
NO330800B1 (no) 2011-07-18
UY25877A1 (es) 2000-08-21
PT2261358E (pt) 2014-07-30
EP2261358B1 (en) 2014-05-14
IL194230A (en) 2013-12-31
ES2480417T3 (es) 2014-07-28
PL204073B1 (pl) 2009-12-31
PT1141306E (pt) 2008-07-30
ATE394489T1 (de) 2008-05-15
AU1764900A (en) 2000-07-31
CN101134775A (zh) 2008-03-05
KR101170203B1 (ko) 2012-07-31
KR100802198B1 (ko) 2008-02-11
ZA200105114B (en) 2002-11-21

Similar Documents

Publication Publication Date Title
NZ512574A (en) Novel streptococcus antigens useful as vaccines
AP2000001886A0 (en) Group B streptococcus antigens.
MXPA03000103A (es) Antigenos de streptococcus.
DE69739981D1 (de) Streptococcus pneumoniae-Antigene und Impfstoffe
ZA965482B (en) Novel antigen.
ATE361365T1 (de) Streptococcus pneumoniae proteine und nukleinsäuren
ATE325620T1 (de) Streptococcus pneumoniae proteine und impfstoffe
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
EP1950302A3 (en) Streptococcus antigens
GB9810084D0 (en) Proteins
WO2001040472A3 (en) Streptococcus pneumoniae antigens
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
EP1219635A3 (en) Chlamydia pneumoniae antigenes
ATE547527T1 (de) Gruppe b streptococcus bvh-a2 und bvh-a3 antigene
BR0111886A (pt) Antìgeno para estreptococos

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SHIRE BIOCHEM INC., CA

Free format text: OLD OWNER(S): BIOCHEM PHARMA INC.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: ID BIOMEDICAL CORPORATION, CA

Free format text: OLD OWNER(S): SHIRE BIOCHEM INC.

RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired